Get started

Financials · CSBR

Champions Oncology Inc. (CSBR) financials

For the twelve months ended Jul 31, 2026, Champions Oncology Inc. reported $60.66M of revenue and -$1.14M of net income.

Revenue, TTM
$60.66M
Revenue growth, YoY
+6.7%
Net income, TTM
-$1.14M
Net margin
-1.9%
Free cash flow, TTM
-$6.14M
Cash
$4.36M
P/S
1.11
Market cap
$67.4M
Annual revenue$59.42M
FY2018FY2026
Annual net income-$1.18M
FY2017FY2026
Annual free cash flow-$5.04M
FY2017FY2026

CSBR revenue and earnings growth

CSBR revenueQ1 2027$15.23M

Quarter YoY
+8.8%
QoQ
+10.1%
FY YoY
+4.4%
5Y CAGR
+7.7%

CSBR revenue was $15.23M in fiscal Q1 2027 (ended Jul 31, 2026), up 8.8% from a year earlier and up 10.1% from the prior quarter. For the full fiscal 2026 it was $59.42M, up 4.4% from fiscal 2025. Compound annual growth was +7.7% over 5 years. It rose in 7 of the last 8 fiscal years. Fiscal 2026 is the highest of the 9 fiscal years on file.

CSBR net incomeQ1 2027-$426.0K

CSBR net income was -$426.0K in fiscal Q1 2027 (ended Jul 31, 2026), compared with -$466.0K a year earlier. For the full fiscal 2026 it was -$1.18M, compared with $4.70M in fiscal 2025.

CSBR EPSQ4 2026-$0.05

CSBR diluted EPS was -$0.05 in fiscal Q4 2026 (ended Apr 30, 2026), compared with -$0.12 a year earlier. For the full fiscal 2026 it was -$0.08, compared with $0.33 in fiscal 2025.

CSBR free cash flowQ1 2027-$547.0K

CSBR free cash flow was -$547.0K in fiscal Q1 2027 (ended Jul 31, 2026), compared with $554.0K a year earlier. For the full fiscal 2026 it was -$5.04M, compared with $7.00M in fiscal 2025.

Export CSV

Income statement

Income statement
Line item
FY2026
Apr 30, 2026
FY2025
Apr 30, 2025
FY2024
Apr 30, 2024
FY2023
Apr 30, 2023
FY2022
Apr 30, 2022
FY2021
Apr 30, 2021
FY2020
Apr 30, 2020
FY2019
Apr 30, 2019
FY2018
Apr 30, 2018
FY2017
Apr 30, 2017
Revenue$59.42M$56.94M$50.16M$53.87M$49.11M$41.04M$32.12M$27.07M$20.24M-
Cost of revenue$30.90M$28.39M$29.40M$29.53M$23.63M$21.45M$17.00M---
Gross profit$28.52M$28.55M$20.75M$24.34M$25.48M$19.59M$15.12M---
Research and development$9.08M$6.83M$9.54M$11.54M$9.37M$7.20M$5.85M$4.80M$4.40M$4.29M
Selling, general and admin$11.15M$9.34M$11.07M$10.24M$9.12M$6.51M$6.61M$4.68M$4.07M$4.96M
Operating income-$1.14M$4.55M-$7.36M-$5.26M$607.0K$366.0K-$1.92M$270.0K-$1.35M-$6.81M
Pre-tax income-$929.0K$4.63M-$7.31M-$5.27M$583.0K$437.0K-$1.96M$231.0K-$1.44M-$6.87M
Income tax$246.0K-$75.0K-$32.0K$68.0K$35.0K$75.0K$130.0K$103.0K$33.0K$19.0K
Net income-$1.18M$4.70M-$7.28M-$5.33M$548.0K$362.0K-$2.09M$128.0K-$1.48M-$6.88M
EPS, basic-$0.08$0.34-$0.54-$0.39$0.04$0.03-$0.18$0.01-$0.13-$0.64
EPS, diluted-$0.08$0.33-$0.54-$0.39$0.04$0.02-$0.18$0.01-$0.13-$0.64
Diluted shares13.8M14.3M13.5M13.5M14.2M14.6M11.8M14.1M11.0M10.7M

Balance sheet

Balance sheet
Line item
FY2026
Apr 30, 2026
FY2025
Apr 30, 2025
FY2024
Apr 30, 2024
FY2023
Apr 30, 2023
FY2022
Apr 30, 2022
FY2021
Apr 30, 2021
FY2020
Apr 30, 2020
FY2019
Apr 30, 2019
FY2018
Apr 30, 2018
FY2017
Apr 30, 2017
Cash and equivalents$4.87M$9.79M$2.62M$10.12M$9.01M$4.69M$8.34M$3.24M$1.01M$3.44M
Receivables$13.18M$11.20M$9.53M$8.01M$9.51M$6.99M$4.77M$4.38M$3.92M$2.27M
Current assets$19.22M$22.36M$13.64M$19.46M$19.66M$12.63M$13.50M$7.92M$5.06M$5.87M
Goodwill$335.0K$335.0K$335.0K$335.0K$335.0K$335.0K$335.0K$669.0K$669.0K$669.0K
Total assets$26.99M$32.34M$26.13M$34.31M$35.38M$27.59M$20.75M$11.27M$8.08M$8.01M
Current liabilities$19.92M$23.85M$21.54M$21.73M$17.48M$11.20M$12.30M$8.03M$7.45M$7.45M
Total liabilities$22.92M$28.57M$28.04M$29.68M$26.28M$20.16M$15.65M$9.03M$8.07M$7.61M
Shareholders' equity$3.94M$3.77M-$1.90M$4.64M$9.10M$7.43M$5.10M$2.14M$3.0K$400.0K

Cash flow

Cash flow
Line item
FY2026
Apr 30, 2026
FY2025
Apr 30, 2025
FY2024
Apr 30, 2024
FY2023
Apr 30, 2023
FY2022
Apr 30, 2022
FY2021
Apr 30, 2021
FY2020
Apr 30, 2020
FY2019
Apr 30, 2019
FY2018
Apr 30, 2018
FY2017
Apr 30, 2017
Operating cash flow-$4.47M$7.39M-$6.14M$3.97M$6.50M-$1.68M$2.90M$1.86M-$1.23M-$2.84M
Capital expenditures$564.0K$389.0K$836.0K$2.87M$2.38M$3.28M$2.22M$834.0K$1.23M$766.0K
Free cash flow-$5.04M$7.00M-$6.97M$1.10M$4.11M-$4.96M$685.0K$1.03M-$2.46M-$3.61M
Investing cash flow-$540.0K-$389.0K-$836.0K-$2.87M-$2.38M-$3.17M-$2.22M-$834.0K-$1.23M-$766.0K
Financing cash flow$99.0K$170.0K-$527.0K$11.0K$207.0K$1.20M$4.42M$1.20M$13.0K$4.32M
Share repurchases-$0$634.0K$74.0K$0-----
Stock-based compensation$1.24M$654.0K$1.12M$864.0K$912.0K$598.0K$600.0K$636.0K$1.00M$2.66M
Depreciation and amortization$1.40M$1.60M$1.90M$2.10M$1.50M$925.0K$825.0K$606.0K$360.0K$168.0K

Key ratios

Key ratios
Line item
FY2026
Apr 30, 2026
FY2025
Apr 30, 2025
FY2024
Apr 30, 2024
FY2023
Apr 30, 2023
FY2022
Apr 30, 2022
FY2021
Apr 30, 2021
FY2020
Apr 30, 2020
FY2019
Apr 30, 2019
FY2018
Apr 30, 2018
FY2017
Apr 30, 2017
Revenue growth, YoY4.4%13.5%-6.9%9.7%19.7%27.8%18.7%33.7%--
Net income growth, YoY----51.4%-----
EPS growth, YoY----100.0%-----
Gross margin48.0%50.1%41.4%45.2%51.9%47.7%47.1%---
Operating margin-1.9%8.0%-14.7%-9.8%1.2%0.9%-6.0%1.0%-6.7%-
Net margin-2.0%8.3%-14.5%-9.9%1.1%0.9%-6.5%0.5%-7.3%-
Free cash flow margin-8.5%12.3%-13.9%2.0%8.4%-12.1%2.1%3.8%-12.1%-
Return on equity-29.8%124.6%--115.1%6.0%4.9%-41.0%6.0%-49200.0%-1721.0%
Return on assets-4.4%14.5%-27.8%-15.5%1.5%1.3%-10.1%1.1%-18.3%-85.9%
Current ratio0.960.940.630.901.131.131.100.990.680.79

Source: XBRL data Champions Oncology Inc. files with the SEC, latest filing dated Sep 11, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-12, first reported Dec 15, 2015.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

CSBR peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
CSBR$60.66M+6.7%-$1.14M-1.9%$67.4M
AMGN$38.90B+8.2%$9.39B24.1%$251.65B
GILD$30.99B+6.5%-$3.86B-12.5%$210.01B
MRNA$2.52B+13.1%-$2.79B-110.5%$107.39B
ARGX$4.25B+88.6%$1.29B30.4%$59.72B
RVMD$0--$1.13B-$43.29B
BIIB$10.30B+2.3%$347.50M3.4%$37.67B
BNTX€2.87B+4.3%-€1.14B-39.6%$21.98B
EXEL$2.50B+9.1%$885.14M35.5%$17.51B

CSBR FAQ

8 questions
  • What is CSBR revenue?
    Champions Oncology Inc. (CSBR) reported $60.66M of revenue for the twelve months ended Jul 31, 2026. That is up 6.7% from the year before. Revenue for fiscal 2026 was $59.42M.
  • Is CSBR profitable?
    No. Champions Oncology Inc. reported a net loss of $1.14M for the twelve months ended Jul 31, 2026.
  • How much cash and debt does CSBR have?
    Champions Oncology Inc. reported $4.36M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is CSBR revenue growing?
    Champions Oncology Inc.'s revenue changed +4.4% in fiscal 2026, to $59.42M. Its compound annual growth rate was +7.7% over 5 years.
  • What is CSBR gross margin?
    Champions Oncology Inc.'s gross profit was $30.22M on $60.66M of revenue for the twelve months ended Jul 31, 2026, a gross margin of 49.8%.
  • What is CSBR free cash flow?
    Champions Oncology Inc. generated -$6.14M of free cash flow for the twelve months ended Jul 31, 2026, which is operating cash flow of -$5.56M less capital expenditures.
  • When did CSBR last report financial results?
    The latest statements here come from Champions Oncology Inc.'s 10-Q filed on Sep 11, 2026, covering the period ended Jul 31, 2026.
  • Where does this CSBR financial data come from?
    Quantisnow builds these statements from the structured XBRL data Champions Oncology Inc. files with the SEC. It is provided for information only and is not investment advice.